Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study.

To investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event.We analyzed 211 CIS patients (age: 28.9±7.8 years) enrolled in the SET study, a multi-center study of hi...

Full description

Bibliographic Details
Main Authors: Dana Horakova, Robert Zivadinov, Bianca Weinstock-Guttman, Eva Havrdova, Jun Qu, Miriam Tamaño-Blanco, Darlene Badgett, Michaela Tyblova, Niels Bergsland, Sara Hussein, Laura Willis, Jan Krasensky, Manuela Vaneckova, Zdenek Seidl, Petra Lelkova, Michael G Dwyer, Ming Zhang, Haoying Yu, Xiaotao Duan, Tomas Kalincik, Murali Ramanathan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3540021?pdf=render
Description
Summary:To investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event.We analyzed 211 CIS patients (age: 28.9±7.8 years) enrolled in the SET study, a multi-center study of high-risk CIS patients. Pre-treatment samples were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) early nuclear antigen-1 (EBNA-1), viral capsid antigen (VCA), early antigen-diffuse (EA-D), 25 hydroxy-vitamin D3 and cotinine levels and HLA DRB1*1501 status. The inclusion criteria required evaluation within 4 months of the initial demyelinating event, 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. All patients were treated with interferon-beta. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months.The time to first relapse decreased and the number of relapses increased with anti-CMV IgG positivity. Smoking was associated with increased number and volume of contrast-enhancing lesions (CEL) during the 2-year period. The cumulative number of CEL and T2 lesions during the 2-year period was greater for individuals in the highest quartile of anti-EBV VCA IgG antibodies. The percent loss of brain volume was increased for those in the highest quartile of with anti-EBV VCA IgG antibodies.Relapses in CIS patients were associated with CMV positivity whereas anti-EBV VCA positivity was associated with progression on MRI measures, including accumulation of CEL and T2 lesions and development of brain atrophy.
ISSN:1932-6203